|Day Low/High||6.73 / 7.22|
|52 Wk Low/High||2.38 / 8.12|
My main focus right now is on stronger defense.
Anyone attempting to navigate this market based on macro-economic analysis is going to have a tough time.
A major theme of late has been the outperformance by post-pandemic names in groups such as biotech.
The biotech sector doesn't look anything like a bear market.
I believe this is just bounce action at this point and not a bottom, but I'm playing it.
The action is not supportive of good chart setups for shorter term trades in individual stocks.
There is nothing in small-caps to suggest that they are as frothy as the big-caps.
Stemline Therapeutics, Entercom Communications and Ocular Therapeutix offer reasons to think their shares will perform better in the New Year.
I am inclined to focus more on counter-trend bounces in weak markets.
Flat markets tend to produce favorable technical setups, but this one may put us to sleep while we wait for further developments.
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.
Markets continue to be nicely in the black two hours into trading as resumption of U.S.-China trade talks have investors in a good mood to start off the second half of trading in 2019. Some small biotechs continue to show some strength this Monday. ...
Its price is determined by emotion more than anything else.
The important thing to remember on days like this is to not read too much into the action.
Other than the Dow, most of major market indices are showing small gains heading into the last hour of trading. The biotech sector has not participated in today's rally and is down some 0.75% on the day so far. I am watching a few small biotech and ...
Wall Street discounting talk of bombing Syria from president.
Whether this market continues to bounce is going to depend a great degree on the FAANG names.
The longer the stock market goes without a better bounce, the bigger the risk.
Right now this is a market for stock pickers and not timers.
2:15 pm update Markets are pretty much where they were 90 minutes ago. The S&P has strengthened a bit and overall equities have held up better than I thought given the potential partial government shutdown this weekend. We will see if stocks hold th...
Dynavax Technologies, Ocular Therapeutix and Neos Therapeutics have big drug approval dates ahead.
Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.
The market and 10-year Treasury yield are taking disappointing first-quarter GDP number in stride. The Chicago PMI came in stronger than expected and growth should rebound in the second quarter. Consumer spending was weak in first quarter, especiall...
Insiders have an edge in this complex sector, so it's worth checking them out.